September 13, 2018 / 12:16 PM / a month ago

BRIEF-Herceptin (Trastuzumab) Subcutaneous (SC) Formulation Approved In Canada For Treatment Of Her2-Positive Breast Cancer

Sept 13 (Reuters) - Roche Holding AG:

* HERCEPTIN® (TRASTUZUMAB) SUBCUTANEOUS (SC) FORMULATION APPROVED IN CANADA FOR TREATMENT OF HER2-POSITIVE BREAST CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below